Author

R. K. Muir

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. B. Olshen· 1 shared A. Renslo· 1 shared B. C. Hann· 1 shared B. Cerikan· 1 shared B. M. Babin· 1 shared C. Peters· 1 shared e. collisson· 1 shared H. Jiang· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. B. Olshen

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivNov 21, 2020

Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19

K. Steuten, H. Kim, J. C. Widen…·M. Bogyo

This study evaluates compounds targeting SARS-CoV-2 proteases Mpro and PLpro, finding limited efficacy for Mpro due to off-target inhibition of host cathepsins and no viable hits for PLpro.

DOI 10.1021/acsinfecdis.0c00815

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivMay 12, 2020

Exploiting KRAS-driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC)

H. Jiang, R. K. Muir, R. L. Gonciarz…·A. Renslo

This paper develops FeADCs, ferrous iron-activatable drug conjugates, to target KRAS-driven cancers with improved tumor selectivity and systemic tolerability.

DOI 10.1084/jem.20210739

mouseexperimental assay

𝕏 PostBluesky